These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 21918742)

  • 1. [Permanent implant brachytherapy for early, organ-confined prostate cancer].
    Agoston P; Major T; Fröhlich G; Baricza K; Szabó Z; Lövey J; Varjas G; Kásler M; Fodor J; Polgár C
    Magy Onkol; 2011 Sep; 55(3):170-7. PubMed ID: 21918742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Brachytherapy boost irradiation in the treatment of high risk, localised prostate cancer. Initial national experience in Hungary].
    Agoston P; Major T; Somogyi A; Szûcs M; Danczig A; Lövey J; Polgár C; Fodor J; Németh G; Kásler M
    Magy Onkol; 2004; 48(1):81-8. PubMed ID: 15105901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Five-year outcome of intraoperative conformal permanent I-125 interstitial implantation for patients with clinically localized prostate cancer.
    Zelefsky MJ; Yamada Y; Cohen GN; Shippy A; Chan H; Fridman D; Zaider M
    Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):65-70. PubMed ID: 17189063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urethra-sparing, intraoperative, real-time planned, permanent-seed prostate brachytherapy: toxicity analysis.
    Zilli T; Taussky D; Donath D; Le HP; Larouche RX; Béliveau-Nadeau D; Hervieux Y; Delouya G
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e377-83. PubMed ID: 21514068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Twelve-month prostate-specific antigen values and perineural invasion as strong independent prognostic variables of long-term biochemical outcome after prostate seed brachytherapy.
    Ding W; Lee J; Chamberlain D; Cunningham J; Yang L; Tay J
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):962-7. PubMed ID: 22494584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraoperative real-time planned conformal prostate brachytherapy: post-implantation dosimetric outcome and clinical implications.
    Zelefsky MJ; Yamada Y; Cohen GN; Sharma N; Shippy AM; Fridman D; Zaider M
    Radiother Oncol; 2007 Aug; 84(2):185-9. PubMed ID: 17692978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
    Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
    J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [PSA bounce after permanent implant prostate brachytherapy may mimic a biochemical failure].
    Toledano A; Chauveinc L; Flam T; Thiounn N; Solignac S; Timbert M; Rosenwald JC; Cosset JM
    Cancer Radiother; 2007 May; 11(3):105-10. PubMed ID: 17158082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate seed implantation using 3D-computer assisted intraoperative planning vs. a standard look-up nomogram: Improved target conformality with reduction in urethral and rectal wall dose.
    Raben A; Chen H; Grebler A; Geltzeiler J; Geltzeiler M; Keselman I; Litvin S; Sim S; Hanlon A; Yang J
    Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1631-8. PubMed ID: 15590195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Favorable toxicity and biochemical control using real-time inverse optimization technique for prostate brachytherapy.
    Raben A; Rusthoven KE; Sarkar A; Glick A; Benge B; Jacobs D; Raben D
    Brachytherapy; 2009; 8(3):297-303. PubMed ID: 19213608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Median 5 year follow-up of 125iodine brachytherapy as monotherapy in men agedGómez-Iturriaga Piña A; Crook J; Borg J; Lockwood G; Fleshner N
    Urology; 2010 Jun; 75(6):1412-6. PubMed ID: 20035986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. (125)I monotherapy using D90 implant doses of 180 Gy or greater.
    Kao J; Stone NN; Lavaf A; Dumane V; Cesaretti JA; Stock RG
    Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):96-101. PubMed ID: 17980505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative study of seed localization and dose calculation on pre- and post-implantation ultrasound and CT images for low-dose-rate prostate brachytherapy.
    Ali I; Algan O; Thompson S; Sindhwani P; Herman T; Cheng CY; Ahmad S
    Phys Med Biol; 2009 Sep; 54(18):5595-611. PubMed ID: 19717887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-specific antigen relapse-free survival in patients with localized prostate cancer treated by brachytherapy.
    Joseph J; Al-Qaisieh B; Ash D; Bottomley D; Carey B
    BJU Int; 2004 Dec; 94(9):1235-8. PubMed ID: 15610096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-specific antigen relapse-free survival and side-effects in 734 patients with up to 10 years of follow-up with localized prostate cancer treated by permanent iodine implants.
    Prada PJ; Juan G; González-Suárez H; Fernández J; Jimenez I; Amón J; Cepeda M
    BJU Int; 2010 Jul; 106(1):32-6. PubMed ID: 20067460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loose seeds vs. stranded seeds: a comparison of critical organ dosimetry and acute toxicity in (125)I permanent implant for low-risk prostate cancer.
    Saibishkumar EP; Borg J; Yeung I; Cummins-Holder C; Landon A; Crook JM
    Brachytherapy; 2008; 7(2):200-5. PubMed ID: 18362087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of hormone therapy on post-implant dosimetry and outcome following Iodine-125 implant monotherapy for localised prostate cancer.
    Ash D; Al-Qaisieh B; Bottomley D; Carey B; Joseph J
    Radiother Oncol; 2005 Jun; 75(3):303-6. PubMed ID: 15890423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary Gleason grade 4 impact on biochemical recurrence after permanent interstitial brachytherapy in Japanese patients with low- or intermediate-risk prostate cancer.
    Uesugi T; Saika T; Edamura K; Nose H; Kobuke M; Ebara S; Abarzua F; Katayama N; Yanai H; Nasu Y; Kumon H
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e219-23. PubMed ID: 21640517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.